The compounding industry is stepping up to fill a gap in the market left by brand-name manufacturers like Novo Nordisk and Eli Lilly, who are facing shortages.
Robin Feldman states, 'It's all about the dollars' as she emphasizes the financial motivations driving the conflict over compounded weight-loss drug supply.
Brand manufacturers argue that compounded versions are too difficult to replicate and claim they are no longer in shortage, trying to curb the competition.
Compounding pharmacies make custom drugs for patients, but now face pushback from big drugmakers as the obesity drug market heats up.
Collection
[
|
...
]